Body Mass Index and Dasatinib for Chronic Phase CML
Posted: Monday, April 27, 2020
For patients with a high body mass index (BMI) who are diagnosed with chronic phase chronic myeloid leukemia (CML), treatment with dasatinib appears to improve cytogenic response time and major molecular response time, compared with imatinib, according to findings from the phase III DASISION study presented at the 2020 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference (Abstract CT09). These same results with dasatinib were not associated, however, with patients who had a normal BMI , concluded Alexander Brun, PhD, of Bristol-Myers Squibb.
“Further validation of these findings is necessary to delineate the role of BMI as a predictive factor of treatment responses in patients with [chronic phase CML],” the authors noted.
In this extended follow-up of the phase IIII trial, the authors enrolled 519 patients with newly diagnosed chronic phase CML and stratified the group by high BMI (at least 25 kg/m2) or normal BMI (less than 25 kg/m2). Of the patients, 259 were treated with dasatinib, including 109 patients with a high BMI, 147 with a low BMI, and 3 with an unknown BMI. In addition, 260 patients received imatinib, including 107 with a high BMI, 147 with a normal BMI, and 6 with an unknown BMI.
For patients with a high BMI treated with dasatinib, the median time to complete cytogenetic response was 3.1 months, a “significant benefit” compared with the same patient subgroup treated with imatinib (6.1 months). Similarly, patients with a high BMI who were treated with dasatinib demonstrated a better major molecular response time (9.2 months) than did those who received imatinib (27.6 months).
However, for patients with a normal BMI, the authors observed “nonsignificant” benefits when comparing dasatinib and imatinib. Those receiving dasatinib had a median time to cytogenetic response of 5.6 months, compared with 6.0 months with imatinib, and a median major molecular response time of 18.0 months versus 21.6 months, respectively.
Disclosure: For full disclosures of the authors, visit hoparx.org.